GlassScriptPhysician profile
Benedicto R Galindo
NPI 1427041672
$7,917.21
in general payments reported to CMS, 2019-2025
25 companies · $719 in 2025
The $719 reported for 2025 was more than what 89% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $705 · 2021: $1,042 · 2022: $1,189 · 2023: $612 · 2024: $1,209 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518 · Education: $21.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.84 |
| Education | $21.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,004.94 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.44 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $712.33 | 2019-2023 | Trulicity, Mounjaro |
| Amarin Pharma, INC. | $627.03 | 2019-2021 | |
| Abbvie INC. | $553.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $438.20 | 2019 | |
| Neurocrine Biosciences, INC. | $416.60 | 2019-2025 | Ingrezza |
| Horizon Therapeutics Plc | $382.48 | 2019-2023 | Krystexxa |
| Allergan, INC. | $345.35 | 2019-2020 | |
| Amgen INC. | $316.26 | 2024-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $292.17 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $179.46 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $152.26 | 2021-2024 | Eliquis |
| Ani Pharmaceuticals, INC. | $147.25 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $129.61 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $115.38 | 2021 | |
| Avanir Pharmaceuticals, INC. | $81.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.31 | 2019 | |
| Neurelis, INC. | $41.25 | 2022-2023 | Valtoco |
| Biogen, INC. | $23.88 | 2020 | |
| Arbor Pharmaceuticals, INC. | $20.25 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.52 | 2021 | |
| Galt Pharmaceuticals, LLC | $13.76 | 2023 | Orphengesic Forte |
| Smith+Nephew, INC. | $12.78 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedicto Galindo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.